Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.

IF 1.8 Q4 ENDOCRINOLOGY & METABOLISM
Journal of Diabetes and Metabolic Disorders Pub Date : 2023-11-27 eCollection Date: 2024-06-01 DOI:10.1007/s40200-023-01341-y
Monica Frazer, Caroline Swift, Andrew Sargent, Michael Leszko, Erin Buysman, Noelle N Gronroos, Sara Alvarez, Tyler J Dunn, Josh Noone, Cory L Gamble
{"title":"Real-world HbA<sub>1c</sub> changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.","authors":"Monica Frazer, Caroline Swift, Andrew Sargent, Michael Leszko, Erin Buysman, Noelle N Gronroos, Sara Alvarez, Tyler J Dunn, Josh Noone, Cory L Gamble","doi":"10.1007/s40200-023-01341-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA<sub>1c</sub>) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).</p><p><strong>Methods: </strong>This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA<sub>1c</sub> measures was calculated. Results were stratified by the latest pre-index HbA<sub>1c</sub> measurement (HbA<sub>1c</sub> greater than or equal to 9.0%, uncontrolled vs. HbA<sub>1c</sub> less than 9%, controlled). Statistical comparisons between HbA<sub>1c</sub> groups were conducted.</p><p><strong>Results: </strong>Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA<sub>1c</sub> of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA<sub>1c</sub> compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).</p><p><strong>Conclusions: </strong>OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-023-01341-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA1c) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).

Methods: This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA1c measures was calculated. Results were stratified by the latest pre-index HbA1c measurement (HbA1c greater than or equal to 9.0%, uncontrolled vs. HbA1c less than 9%, controlled). Statistical comparisons between HbA1c groups were conducted.

Results: Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA1c of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA1c compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).

Conclusions: OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.

2 型糖尿病患者开始接受每周一次的赛马鲁肽治疗后的真实 HbA1c 变化和处方特征。
目的:本研究的目的是评估患者、处方者和剂量特征,并评估每周处方一次semaglutide的糖尿病患者(OW sema T2D)的糖化血红蛋白(HbA1c)变化:本研究是一项基于索赔的回顾性研究,使用的是 Optum 研究数据库。样本包括在2018年1月1日至2019年12月31日期间至少有一次OW sema T2D理赔、连续加入医疗计划并在指数前或指数后期间诊断为2型糖尿病(T2DM)的成年患者。收集了使用 OW sema T2D 的患者的人口统计学和临床特征、剂量和处方专业,并计算了指数前和指数后 HbA1c 测量值之间的变化。结果按指数前最新的 HbA1c 测量值进行分层(HbA1c 大于或等于 9.0%,未受控制;HbA1c 小于 9%,已受控制)。HbA1c 组之间进行了统计比较:大多数患者(76.3%)服用了 0.25/0.50 毫克剂量的 OW sema T2D。患者的 HbA1c 总体下降了 0.8%,与控制糖尿病患者相比,未控制糖尿病患者的平均 HbA1c 下降幅度更大(-2.1% 对 -0.3%,P 结论:OW sema T2D 对糖尿病患者有显著疗效:OW sema T2D 是现实世界中治疗 T2DM 的有效方法。未来的研究应进一步调查这种药物在现实世界中的使用模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes and Metabolic Disorders
Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine
CiteScore
4.80
自引率
3.60%
发文量
210
期刊介绍: Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信